ArticleThe Journal of clinical investigation2008
Heparan sulfate and syndecan-1 are essential in maintaining murine and human intestinal epithelial barrier function.
Article in The Journal of clinical investigation, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01430039 (Syndecan-1 as a Surrogate Marker for Inflammatory Bowel Disease), which is not on this map. Cited by 69 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Syndecan-1 as a Surrogate Marker for Inflammatory Bowel Disease
Who cites it
69 citing papers in PubMed, 149 citations in OpenAlex.
- Malnutrition enteropathy in Zambian and Zimbabwean children with severe acute malnutrition: A multi-arm randomized phase II trial.Nature communications · 2024Trial
- Trial
- Circulating and Respiratory Biomarkers in Sepsis-Induced ARDS: Diagnostic and Prognostic Insights - A Narrative Review.Journal of inflammation research · 2026Review
- Clinical characteristics and risk factors of protein-losing enteropathy: a retrospective study.Frontiers in immunology · 2026Article
- Serum-soluble SDC1 in septic patients is rich in heparan sulfate, which affects the ELISA quantification values.Biochemistry and biophysics reports · 2025Article
- Immunohistochemical evaluation of LGR5, CD71, CD138 and CXCR3 markers in the small bowel mucosa of participants with celiac disease and persons with normal bowel mucosa.Journal of molecular histology · 2025Article
- The fibrin-derived peptide FX06 protects human pulmonary endothelial cells against the COVID-19-triggered cytokine storm.Frontiers in immunology · 2025Article
- Structural and mechanistic characterization of bifunctional heparan sulfate N-deacetylase-N-sulfotransferase 1.Nature communications · 2024Article
- Gas Plasma Exposure Alters Microcirculation and Inflammation during Wound Healing in a Diabetic Mouse Model.Antioxidants (Basel, Switzerland) · 2024Article
- Predictive Value of SYN-1 Levels for Mortality in Sepsis Patients in the Emergency Department.Journal of inflammation research · 2024Article
- Heparanase-A single protein with multiple enzymatic and nonenzymatic functions.Proteoglycan research · 2023Review
- Identification of a prototype human gutFrontiers in microbiology · 2023Article
- Hungatella hathewayi, an Efficient Glycosaminoglycan-DegradingApplied and environmental microbiology · 2022Article
- Review
- Mechanism-based heparanase inhibitors reduce cancer metastasis in vivo.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Hyaluronidase-1-mediated glycocalyx impairment underlies endothelial abnormalities in polypoidal choroidal vasculopathy.BMC biology · 2022Article
- Role of heparinase in the gastrointestinal dysfunction of sepsis (Review).Experimental and therapeutic medicine · 2022Review
- Investigation of the invasion mechanism mediated by the outer membrane protein PagN of Salmonella Typhimurium.BMC microbiology · 2021Article
- Diagnosis and Management of Lymphatic Disorders in Congenital Heart Disease.Current cardiology reports · 2020Review
- The Role of Glycosaminoglycans in Protection from Neonatal Necrotizing Enterocolitis: A Narrative Review.Nutrients · 2020Review
9 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 3 countries.
Funding
Abstract
Patients with protein-losing enteropathy (PLE) fail to maintain intestinal epithelial barrier function and develop an excessive and potentially fatal efflux of plasma proteins. PLE occurs in ostensibly unrelated diseases, but emerging commonalities in clinical observations recently led us to identify key players in PLE pathogenesis. These include elevated IFN-gamma, TNF-alpha, venous hypertension, and the specific loss of heparan sulfate proteoglycans from the basolateral surface of intestinal epithelial cells during PLE episodes. Here we show that heparan sulfate and syndecan-1, the predominant intestinal epithelial heparan sulfate proteoglycan, are essential in maintaining intestinal epithelial barrier function. Heparan sulfate- or syndecan-1-deficient mice and mice with intestinal-specific loss of heparan sulfate had increased basal protein leakage and were far more susceptible to protein loss induced by combinations of IFN-gamma, TNF-alpha, and increased venous pressure. Similarly, knockdown of syndecan-1 in human epithelial cells resulted in increased basal and cytokine-induced protein leakage. Clinical application of heparin has been known to alleviate PLE in some patients but its unknown mechanism and severe side effects due to its anticoagulant activity limit its usefulness. We demonstrate here that non-anticoagulant 2,3-de-O-sulfated heparin could prevent intestinal protein leakage in syndecan-deficient mice, suggesting that this may be a safe and effective therapy for PLE patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.